Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer.
CONCLUSION: The clinical therapeutic effect of BEV combined with paclitaxel in patients with recurrent ovarian cancer was improved, suggesting it might be beneficial for the treatment of ovarian cancer.
PMID: 31424654 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Allergy | Allergy & Immunology | Avastin | Cancer | Cancer & Oncology | Gastroenterology | Ovarian Cancer | Ovaries